Webinar Date/Time: Wed, Jul 24, 2024 12:00 PM EDT
Discover a powerful, high-speed workflow for developability assessment during clone selection, manufacturing scale-up and QC of protein therapeutics. Gain information for confident identification and localization of multiple critical PTMs utilizing the Intabio ZT system for in depth subunit analysis.
Register Free: https://www.chromatographyonline.com/lcgc_w/guide-decisions
Event Overview:
With increasing complexity of novel biopharmaceuticals comes new challenges in developing stable cell lines to produce these treatements. Strategies to gain more information on critical post translational modifications in early development can significantly accelerate drug development timelines. Critical information on drug molecules at the intact level can reduce risk and streamline both downstream and upstream processes. This can be achieved by reducing the time required to gain this information and enabling the use of mass spectrometry assays at critical stages in early development.
This webinar will cover the use of an integrated icIEF-UV/MS workflow on the Intabio ZT system to identify multiple critical post translational modifications (PTMs) at the subunit level. Information gained from this 2-dimensional analysis provides glycan localization, deamidation, C terminal processing, N terminal cyclization, N linked glycosylation with terminal alpha Galactose and neuraminic acid, expanding on the core charge variant characterization applications of the Intabio ZT system.
Key Learning Objectives:
Who Should Attend:
Speaker:
Scott Mack
Principal Scientist
SCIEX
Scott Mack is a Principal Scientist and co-inventor of the Microchip Electrophoresis technology employed in the Intabio ZT system from SCIEX. Prior to joining SCIEX, Scott led icIEF assay development and system integration efforts on the Maurice System. In addition, he developed the advanced cIEF methodology for the PA 800 Plus system and pioneered enhanced cIEF-MS analysis with David Chen’s Lab at the University of British Columbia
Register Free: https://www.chromatographyonline.com/lcgc_w/guide-decisions
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
Teva and Samsung Bioepis Launch Biosimilar Eculizumab in US Market
April 17th 2025Eculizumab-aagh (EPYSQLI) is now available in the US to treat patients living with difficult-to-treat rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.